The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. CEO of Vivlion.

Genomics 52

Genomics Genome Licensing Licensing 52

BioTech 365

JUNE 30, 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagents offering DUBLIN & TOKYO–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad … Continue reading →

Genome 40

Genome Genomics Licensing Licensing 40

BioTech 365

FEBRUARY 23, 2021

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →

Life Science 40

Life Science Genome Genomics Licensing 40

BioTech 365

OCTOBER 13, 2020

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genomics 40

Genomics Genome Reagent Gene Editing 40

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. For each production process, you have to generate the plasmids in huge quantities with GMP quality and then do a transient transfection, meaning you mix them with a transfection reagent and add that to the cells in a very controlled way,” explains Faust.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Pharmaceutical Technology

FEBRUARY 15, 2023

Existing compositions have proven effective but a complex landscape of intellectual property (IP) and licensing agreements make accessing these compositions complex for new parties when attempting to get to the clinic. Outlook The era of mRNA-based genomic medicines is on the horizon.

Bioassay 130

Bioassay RNA Development Drugs 130

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genome Genomics 52